Key Points
- Insmed CEO William Lewis sold 21,398 shares on June 25 at an average price of $103.32, totaling about $2.21 million. The transaction reduced his direct holdings by 7.63% and was made under a pre-arranged Rule 10b5-1 trading plan.
- Insmed’s stock was trading around $103.38, near the lower end of its 52-week range of $90.39 to $212.75. The shares were down 1.0% in the session, with the stock also trading below both its 50-day and 200-day moving averages.
- The company recently beat earnings expectations, reporting Q1 EPS of -$0.76 versus estimates of -$0.90 and revenue of $305.96 million, up 229.7% year over year. Despite the improvement, analysts still expect a full-year loss, and the consensus rating remains “Moderate Buy.”
Insmed, Inc. (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 21,398 shares of the firm's stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $103.32, for a total value of $2,210,841.36. Following the transaction, the chief executive officer directly owned 258,917 shares in the company, valued at approximately $26,751,304.44. The trade was a 7.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
William Lewis also recently made the following trade(s):
- On Wednesday, June 3rd, William Lewis sold 7,605 shares of Insmed stock. The shares were sold at an average price of $102.27, for a total value of $777,763.35.
- On Thursday, April 16th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $143.97, for a total value of $1,540,335.03.
- On Monday, April 6th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $163.22, for a total value of $1,746,290.78.
Insmed Trading Down 1.0%
NASDAQ:INSM opened at $103.38 on Friday. The company has a market capitalization of $22.41 billion, a PE ratio of -17.98 and a beta of 0.79. Insmed, Inc. has a 52-week low of $90.39 and a 52-week high of $212.75. The stock's 50 day moving average price is $112.90 and its 200 day moving average price is $143.82. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80.
Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating analysts' consensus estimates of ($0.90) by $0.14. The company had revenue of $305.96 million during the quarter, compared to analysts' expectations of $300.81 million. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The firm's revenue for the quarter was up 229.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.42) earnings per share. On average, research analysts anticipate that Insmed, Inc. will post -2.55 EPS for the current year.
Institutional Trading of Insmed
Several hedge funds have recently made changes to their positions in the company. Empowered Funds LLC boosted its holdings in shares of Insmed by 32.6% in the first quarter. Empowered Funds LLC now owns 51,986 shares of the biopharmaceutical company's stock valued at $8,501,000 after acquiring an additional 12,775 shares in the last quarter. Defilade Capital Management L.P. raised its holdings in Insmed by 289.8% during the first quarter. Defilade Capital Management L.P. now owns 194,909 shares of the biopharmaceutical company's stock worth $31,872,000 after purchasing an additional 144,909 shares in the last quarter. Parallel Advisors LLC lifted its position in Insmed by 13.1% in the first quarter. Parallel Advisors LLC now owns 2,291 shares of the biopharmaceutical company's stock valued at $375,000 after purchasing an additional 266 shares during the period. NewEdge Advisors LLC lifted its position in Insmed by 133.0% in the first quarter. NewEdge Advisors LLC now owns 6,015 shares of the biopharmaceutical company's stock valued at $984,000 after purchasing an additional 3,433 shares during the period. Finally, NWI Management LP boosted its holdings in Insmed by 2.6% in the 1st quarter. NWI Management LP now owns 1,014,000 shares of the biopharmaceutical company's stock valued at $165,809,000 after purchasing an additional 25,540 shares in the last quarter.
Analyst Upgrades and Downgrades
Several research firms recently commented on INSM. HC Wainwright reiterated a "buy" rating on shares of Insmed in a research report on Friday, May 8th. Weiss Ratings reissued a "sell (d-)" rating on shares of Insmed in a research report on Tuesday, April 21st. Guggenheim lowered their price objective on shares of Insmed from $230.00 to $226.00 and set a "buy" rating on the stock in a research report on Friday, May 8th. Royal Bank Of Canada dropped their price objective on shares of Insmed from $205.00 to $195.00 and set an "outperform" rating on the stock in a research note on Friday, June 5th. Finally, Stifel Nicolaus upped their target price on shares of Insmed from $205.00 to $208.00 and gave the company a "buy" rating in a report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $211.86.
Read Our Latest Stock Analysis on INSM
About Insmed
(
Get Free Report)
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.
The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
